OLD Second National Bank of Aurora Has $1.49 Million Stake in Bristol-Myers Squibb (NYSE:BMY)

OLD Second National Bank of Aurora lowered its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 11.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 29,094 shares of the biopharmaceutical company’s stock after selling 3,919 shares during the quarter. OLD Second National Bank of Aurora’s holdings in Bristol-Myers Squibb were worth $1,493,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Norges Bank acquired a new position in Bristol-Myers Squibb during the fourth quarter valued at approximately $1,873,696,000. Northern Trust Corp grew its holdings in Bristol-Myers Squibb by 5.8% during the third quarter. Northern Trust Corp now owns 25,292,711 shares of the biopharmaceutical company’s stock valued at $1,467,989,000 after purchasing an additional 1,394,158 shares during the period. Moneta Group Investment Advisors LLC grew its holdings in Bristol-Myers Squibb by 114,228.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 21,469,785 shares of the biopharmaceutical company’s stock valued at $1,544,751,000 after purchasing an additional 21,451,006 shares during the period. Invesco Ltd. lifted its stake in Bristol-Myers Squibb by 8.6% in the third quarter. Invesco Ltd. now owns 15,606,587 shares of the biopharmaceutical company’s stock valued at $905,806,000 after buying an additional 1,240,902 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Bristol-Myers Squibb by 1.8% in the first quarter. Charles Schwab Investment Management Inc. now owns 11,005,473 shares of the biopharmaceutical company’s stock valued at $803,730,000 after buying an additional 197,000 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BMY. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday. Wells Fargo & Company boosted their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday. Bank of America lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $68.00 to $60.00 in a research report on Wednesday, January 3rd. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Finally, Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus price target of $61.18.

Bristol-Myers Squibb Price Performance

Shares of BMY stock traded up $0.34 on Thursday, reaching $48.18. The company had a trading volume of 2,609,413 shares, compared to its average volume of 15,667,863. The stock has a market capitalization of $97.65 billion, a PE ratio of 12.46, a price-to-earnings-growth ratio of 1.49 and a beta of 0.39. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 1.24. Bristol-Myers Squibb has a one year low of $47.58 and a one year high of $70.93. The business’s 50-day moving average is $51.26 and its 200 day moving average is $51.59.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. The firm had revenue of $11.48 billion during the quarter, compared to analysts’ expectations of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The business’s revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.82 earnings per share. Equities research analysts forecast that Bristol-Myers Squibb will post 6.47 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.98%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 62.18%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.